Nanomedicine for Intranasal Delivery to Improve Brain Uptake

Patel, Amit A.; Patel, Ravish J.; Patel, Shachi R.

doi:10.2174/1567201814666171013150534

Cited by 27 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another possible approach in the administration of PENs, intranasal administration, has been demonstrated. Intranasal administration has been commonly used for the treatment of pulmonary disease, and it provides advantages such as allowing local delivery; the delivery of a concentrated dose to the target organ; and direct delivery to the respiratory system, the upper nose, and brain [ [121] , [122] , [123] , [124] , [125] – 126 ]. Zhuang et al reported the use of intranasal route-based GNV and miRNA targeting brain tumor [127] .…”

Section: Applications Of Pens and Their Therapeutic Effectsmentioning

confidence: 99%

Plant-derived exosome-like nanoparticles and their therapeutic activities

Kim

Zhang

et al. 2022

Asian Journal of Pharmaceutical Sciences

160

127

View full text Add to dashboard Cite

Section: Applications Of Pens and Their Therapeutic Effectsmentioning

confidence: 99%

Plant-derived exosome-like nanoparticles and their therapeutic activities

Kim

Zhang

et al. 2022

Asian Journal of Pharmaceutical Sciences

160

127

View full text Add to dashboard Cite

“…Most of these treatments for neurodegenerative diseases simply reduced the disease’s progression rather than curing it entirely. Majority of hydrophilic compounds are unable to cross the BBB, owing to the presence of the efflux transporters like P-glycoprotein (P-gp) and other multi-drug-related protein transporters ( Matsumoto et al, 2017 ; Patel et al, 2018 ). Due to their poor ability to cross the BBB, high first-pass effect, and frequent off-site targeting ( Goel et al, 2022 ), and prospective peptide-based ( Ayyalasomayajula and Suresh, 2018 ; Trapani et al, 2018 ) or gene delivery ( Malhotra et al, 2013 )-based therapies continue to be in the translational phase ( Goel, et al, 2022 ).…”

Section: Alzheimer’s Diseasementioning

confidence: 99%

Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects

Rajput

Dhapte‐Pawar

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is one of the neurological ailments which continue to represent a major public health challenge, owing to increased life expectancy and aging population. Progressive memory loss and decrease in cognitive behavior, owing to irreversible destruction of neurons along with expensive therapeutic interventions, call for an effective, alternate, yet affordable treatment for Alzheimer’s disease. Safe and effective delivery of neurotherapeutics in Alzheimer’s like central nervous system (CNS) disorders still remains elusive despite the major advances in both neuroscience and drug delivery research. The blood–brain barrier (BBB) with its tight endothelial cell layer surrounded by astrocyte foot processes poses as a major barrier for the entry of drugs into the brain. Nasal drug delivery has emerged as a reliable method to bypass this blood–brain barrier and deliver a wide range of neurotherapeutic agents to the brain effectively. This nasal route comprises the olfactory or trigeminal nerves originating from the brain and terminating into the nasal cavity at the respiratory epithelium or olfactory neuroepithelium. They represent the most direct method of noninvasive entry into the brain, opening the most suitable therapeutic avenue for treatment of neurological diseases. Also, drugs loaded into nanocarriers can have better interaction with the mucosa that assists in the direct brain delivery of active molecules bypassing the BBB and achieving rapid cerebrospinal fluid levels. Lipid particulate systems, emulsion-based systems, vesicular drug delivery systems, and other nanocarriers have evolved as promising drug delivery approaches for the effective brain delivery of anti-Alzheimer’s drugs with improved permeability and bioavailability via the nasal route. Charge, size, nature of neurotherapeutics, and formulation excipients influence the effective and targeted drug delivery using nanocarriers via the nasal route. This article elaborates on the recent advances in nanocarrier-based nasal drug delivery systems for the direct and effective brain delivery of the neurotherapeutic molecules. Additionally, we have attempted to highlight various experimental strategies, underlying mechanisms in the pathogenesis and therapy of central nervous system diseases, computational approaches, and clinical investigations pursued so far to attain and enhance the direct delivery of therapeutic agents to the brain via the nose-to-brain route, using nanocarriers.

show abstract

“…Several nasally administered formulations proved their efficacy for delivering drugs to the brain in NDs [459][460][461][462][463][464]. The nanosystems mainly used are nanoemulsions [465,466] and liposomes [467,468], but also polymeric NPs [469] and SLNs [470].…”

Section: Nanosystems For Nose-to-brain Drug Delivery In the Treatment...mentioning

confidence: 99%

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

et al. 2021

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) represent a heterogeneous group of aging-related disorders featured by progressive impairment of motor and/or cognitive functions, often accompanied by psychiatric disorders. NDs are denoted as ‘protein misfolding’ diseases or proteinopathies, and are classified according to their known genetic mechanisms and/or the main protein involved in disease onset and progression. Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) are included under this nosographic umbrella, sharing histopathologically salient features, including deposition of insoluble proteins, activation of glial cells, loss of neuronal cells and synaptic connectivity. To date, there are no effective cures or disease-modifying therapies for these NDs. Several compounds have not shown efficacy in clinical trials, since they generally fail to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells that greatly limits the brain internalization of endogenous substances. By engineering materials of a size usually within 1–100 nm, nanotechnology offers an alternative approach for promising and innovative therapeutic solutions in NDs. Nanoparticles can cross the BBB and release active molecules at target sites in the brain, minimizing side effects. This review focuses on the state-of-the-art of nanoengineered delivery systems for brain targeting in the treatment of AD, PD and HD.

show abstract

Nanomedicine for Intranasal Delivery to Improve Brain Uptake

Cited by 27 publications

References 0 publications

Plant-derived exosome-like nanoparticles and their therapeutic activities

Plant-derived exosome-like nanoparticles and their therapeutic activities

Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

Contact Info

Product

Resources

About